Panobacumab: Difference between revisions
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
m Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot |
||
| (15 intermediate revisions by 11 users not shown) | |||
| Line 1: | Line 1: | ||
{{short description|Monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 458269582 |
||
| image = |
| image = |
||
| ⚫ | |||
| ⚫ | |||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = u |
| source = u |
||
| target = ''[[Pseudomonas aeruginosa]]'' [[serotype]] IATS O11 |
| target = ''[[Pseudomonas aeruginosa]]'' [[serotype]] IATS O11 |
||
| ⚫ | |||
| ⚫ | |||
| tradename = |
| tradename = |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
||
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
||
| Line 21: | Line 21: | ||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| ⚫ | |||
| ⚫ | |||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| Line 28: | Line 27: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| Line 40: | Line 38: | ||
| UNII = 62B4OXU259 |
| UNII = 62B4OXU259 |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| molecular_weight = 879.9 [[kDa]] |
|||
}} |
}} |
||
'''Panobacumab''' (proposed [[International Nonproprietary Name|INN]]) is a [[monoclonal antibodies|monoclonal antibody]] designed as an [[antibacterial]] against ''[[Pseudomonas aeruginosa]]''.<ref name="INN">[ |
'''Panobacumab''' (proposed [[International Nonproprietary Name|INN]]) is a [[monoclonal antibodies|monoclonal antibody]] designed as an [[antibacterial]] against ''[[Pseudomonas aeruginosa]]''.<ref name="INN">[https://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy)], ''World Health Organization''.</ref> |
||
It is a fully human [[pentamer]]ic [[IgM]] antibody with a mouse [[J chain]].<ref name="INN" /> |
It is a fully human [[pentamer]]ic [[IgM]] antibody with a mouse [[J chain]].<ref name="INN" /> |
||
[[Image:IgM.png|thumb|left|Panobacumab molecule consisting of five base units.<br />1: Base unit. <br />2: [[Heavy chain]]s.<br />3: [[Light chain]]s.<br />4: [[J chain]].<br />5: Intermolecular [[disulfide bond]]s.]] |
[[Image:IgM.png|thumb|left|Panobacumab molecule consisting of five base units.<br />1: Base unit. <br />2: [[Immunoglobulin heavy chain|Heavy chain]]s.<br />3: [[Immunoglobulin light chain|Light chain]]s.<br />4: [[J chain]].<br />5: Intermolecular [[disulfide bond]]s.]] |
||
==Development== |
|||
Panobacumab is being developed by [[Aridis Pharmaceuticals]]. As of November 15th it is in phase 2 clinical trials. The originator was [[Berna Biotech]].<ref name="Spring">{{cite web |url=https://adisinsight.springer.com/drugs/800024401 |accessdate=15 November 2019|title=Panobacumab - Aridis Pharmaceuticals - AdisInsight}}</ref> |
|||
The mechanism of action is as a [[lipopolysaccharide]] inhibitor.<ref name="Spring"/> |
|||
==References== |
==References== |
||
| Line 57: | Line 60: | ||
{{Monoclonals for infectious disease and toxins}} |
{{Monoclonals for infectious disease and toxins}} |
||
[[Category:Monoclonal antibodies]] |
|||
[[Category:Experimental monoclonal antibodies]] |
|||
{{antiinfective-drug-stub}} |
{{antiinfective-drug-stub}} |
||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||